Atreca, Inc. Profile Avatar - Palmy Investing

Atreca, Inc.

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and t…

Biotechnology
US, South San Francisco [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of BCEL's Analysis
CIK: 1532346 CUSIP: 04965G109 ISIN: US04965G1094 LEI: - UEI: -
Secondary Listings
BCEL has no secondary listings inside our databases.